Vincerx Pharma, Inc.
VINC
$0.8145
$0.00550.68%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -22.53% | -29.46% | -31.96% | -27.79% | -22.07% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -43.79% | -46.55% | -44.52% | -38.00% | -31.71% |
| Operating Income | 43.79% | 46.55% | 44.52% | 38.00% | 31.71% |
| Income Before Tax | 41.83% | 48.11% | 38.02% | 36.24% | 20.15% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 41.83% | 48.11% | 38.02% | 36.24% | 20.15% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 41.83% | 48.11% | 38.02% | 36.24% | 20.15% |
| EBIT | 43.79% | 46.55% | 44.52% | 38.00% | 31.71% |
| EBITDA | 43.83% | 46.59% | 44.55% | 38.02% | 31.74% |
| EPS Basic | 48.71% | 49.57% | 38.76% | 37.00% | 21.10% |
| Normalized Basic EPS | 48.71% | 48.31% | 36.18% | 34.43% | 17.63% |
| EPS Diluted | 48.71% | 49.57% | 38.76% | 37.00% | 21.10% |
| Normalized Diluted EPS | 48.71% | 48.31% | 36.18% | 34.43% | 17.63% |
| Average Basic Shares Outstanding | 22.47% | 10.98% | 1.17% | 1.27% | 1.35% |
| Average Diluted Shares Outstanding | 22.47% | 10.98% | 1.17% | 1.27% | 1.35% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
